Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

Area of Science:

• Pediatric Oncology
• Hematology
• Immunotherapy

Background:

• B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer.
• Relapsed B-cell ALL is a major cause of cancer-related death in children.
• Blinatumomab, a bispecific T-cell engager, is being investigated to improve outcomes.

Purpose of the Study:

• To evaluate the efficacy of adding blinatumomab to chemotherapy for newly diagnosed standard-risk B-cell ALL in children.
• To assess the impact on disease-free survival.

Main Methods:

• A phase 3 trial randomly assigned children with newly diagnosed standard-risk B-cell ALL to chemotherapy alone or chemotherapy plus blinatumomab.
• The primary endpoint was disease-free survival.
• Interim analysis led to early termination of randomization.

Main Results:

• Adding blinatumomab to chemotherapy resulted in a 3-year disease-free survival of 96.0% compared to 87.9% with chemotherapy alone.
• This improvement was observed in both average and higher relapse risk groups.
• While rare, grade 3 or higher cytokine release syndrome, seizures, and sepsis occurred; however, nonfatal sepsis and catheter-related infections were higher in the blinatumomab group for average relapse risk patients.

Conclusions:

• Blinatumomab significantly improved disease-free survival in children with newly diagnosed standard-risk B-cell ALL.
• The addition of blinatumomab to combination chemotherapy is an effective strategy for this patient population.
• Further research may explore optimizing blinatumomab administration to mitigate infection risks.